D-Aspartic Acid
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Compound | D-Aspartic acid (DAA, D-aspartate) |
|---|---|
| Chemical class | D-enantiomer of aspartic acid — an endogenous signalling molecule |
| CAS | 1783-96-6 (D-aspartic acid) · 56-84-8 (L-aspartic acid) |
| Molecular weight | 133.10 g/mol |
| Endogenous sites | Pituitary, testes and pineal gland — regulated by D-aspartate oxidase |
| Evidence position | Initial testosterone finding not replicated; one trial found a decrease at 6 g |
| Claim strength | High for the endogenous biology; the testosterone claim is unsupported |
| Buy from Herbuno | D-Aspartic Acid 99% Powder · L-Aspartic Acid 99% Powder |
| Origin | Processed / Sourced from India |
| MOQ | R&D 100 g / 250 g (subject to stock) · Pilot batch 1–5 kg · Bulk 10 kg, 25 kg and above |
| Lead Time | Dispatch within 72 hrs from stock · fresh-batch production (typically 50 kg+): 10 working days |
| Documentation | CoA & MSDS standard with every lot |
Name origin: The D-enantiomer of aspartic acid, which Plisson obtained in 1827 by hydrolysing asparagine, itself named for Asparagus. The D-form is unusual among D-amino acids in being a genuine endogenous constituent of mammalian tissue rather than a laboratory curiosity or a bacterial product.
Why it is biologically real: D-aspartate occurs naturally in mammalian neuroendocrine tissue, concentrated in the pituitary, testes and pineal gland, where its concentrations change with development and with endocrine state. Its levels are controlled by D-aspartate oxidase, a dedicated degradative enzyme, and aspartate racemase activity generates it from L-aspartate. The existence of a dedicated synthetic and degradative apparatus is strong evidence that D-aspartate has a signalling function rather than being metabolic noise, and that part of the science is sound.
The proposed mechanism: The hypothesis is two-tiered. In the hypothalamus, D-aspartate is proposed to increase gonadotropin-releasing hormone release, raising luteinising hormone and consequently testicular testosterone synthesis. In the testis itself, D-aspartate is proposed to act on Leydig cells, with reported effects on steroidogenic acute regulatory protein expression. Both tiers have supporting work in rodent and in vitro systems.
Commercial source: D-aspartic acid is obtained by resolution of the racemate or by enzymatic routes, and is a distinct and more expensive article than L-aspartic acid. The price differential creates a substitution incentive, which makes chiral confirmation a practical rather than theoretical specification requirement.
Evidence for D-Aspartic Acid Applications
The testosterone claim rests on one finding that subsequent trials did not reproduce. An initial study in men reported increases in luteinising hormone and testosterone after approximately 2.7 grams daily for 12 days, and that result drove the ingredient's commercial adoption. Subsequent controlled trials in resistance-trained men at 3 grams daily for 28 days reported no change in total or free testosterone, and a further trial examining both 3 and 6 grams found no increase at either dose — with total testosterone reduced in the 6 gram arm. Meta-analytic appraisal in trained populations has found no effect. Claim strength: High that the claim is unsupported.
The negative result at the higher dose is the finding that most deserves stating, because it runs against the usual dose-response assumption. Supplement marketing generally implies that if a dose does not work, more will; here the trial examining 6 grams reported lower total testosterone than control. The mechanism proposed for that is D-aspartate oxidase upregulation or feedback inhibition within the pathway, which is plausible but unestablished. Regardless of mechanism, a product recommending a higher dose to improve results is advising against the available evidence. Claim strength: Moderate.
The endogenous biology is real and should not be dismissed along with the claim. D-aspartate's presence in pituitary, testes and pineal tissue, its developmental regulation, the existence of D-aspartate oxidase as a dedicated degradative enzyme, and aspartate racemase activity together establish it as a signalling molecule rather than a contaminant. Rodent and in vitro work supports roles in gonadotropin release and in Leydig cell steroidogenesis. What has not translated is the inference that oral supplementation in healthy adult men perturbs that system usefully. Claim strength: High for the biology, Emerging for the translation.
A reasonable hypothesis for the discrepancy is population and baseline, not that the initial study was wrong. The original cohort differed from the later resistance-trained cohorts in training status and probably in baseline androgen status, and an effect present in untrained or lower-baseline men could plausibly be absent in trained men near their physiological ceiling. The trials that would test this have not been done. The honest position is that the claim is not supported in the population products target, and that a narrower claim has not been established either. Claim strength: Emerging.
D-aspartic acid is not L-aspartic acid, and the distinction matters commercially in both directions. L-aspartic acid is the proteinogenic form, a urea cycle and nucleotide synthesis participant and the aspartame feedstock, with none of the endocrine claims. D-aspartic acid is a separate and more expensive article. Because the premium sits on the D-form, the substitution exposure runs toward L- supplied against a D- specification, and a standard amino acid assay will not distinguish them. Claim strength: High.
Tolerability appears acceptable at the doses studied, with the usual limits on what short trials establish. Reported adverse effects in the trials were minor, chiefly gastrointestinal, and no serious events were attributed to it. No tolerable upper intake level has been established and no long-term safety data exist. Because the pathway involved is endocrine, and because one trial reported a testosterone decrease at the higher dose, extended high-dose use is not something the evidence base supports characterising as benign. Claim strength: Moderate.
Sourcing D-aspartic acid from Herbuno. We supply D-aspartic acid at 99% and L-aspartic acid as separate articles.
We will supply it and we will not support a testosterone claim on it. The initial finding was not replicated in resistance-trained men at 3 grams, and a trial examining 6 grams reported total testosterone lower than control. If a customer is specifying DAA on the strength of the 2009 study, they should see the replication record first. Specify the isomer by CAS number with chiral confirmation — the premium sits on the D-form, so the substitution exposure runs toward L-. All lots ship with CoA and MSDS; request a quotation for pilot or bulk volumes.
Dosage & Formulator Specification
D-aspartic acid is dosed as the free amino acid at 99%, with no salt conversion. Doses in the trial literature are approximately 2.7 grams daily in the original study and 3 to 6 grams daily in the replication attempts. There is no established effective dose, because no dose has been shown effective in the population products target, and the 6 gram arm of one trial reported lower total testosterone than control. A formulator reproducing a published protocol should reproduce the one that failed to find an effect as readily as the one that did, and know which is which.
Claim construction is the governing issue and the boundaries are clear. Defensible: D-aspartate is an endogenous signalling molecule present in pituitary, testes and pineal tissue, regulated by D-aspartate oxidase, with rodent and in vitro work supporting roles in gonadotropin release and Leydig cell steroidogenesis. Not defensible: any statement that oral supplementation raises testosterone in healthy adult men, which has been tested and not supported. Also not defensible: a dose-escalation recommendation, which the 6 gram finding argues against.
Handling resembles L-aspartic acid and is dominated by low solubility. D-aspartic acid dissolves poorly in water, in the region of 0.5 grams per 100 millilitres at room temperature, which makes liquid applications difficult at meaningful concentration; solubility rises sharply with pH as the carboxyl groups deprotonate, so a sodium or potassium salt is the practical route for liquids. The free acid is a free-flowing crystalline powder, not notably hygroscopic, with a sour taste, and contributes a meaningful acid load in reconstituted formats.
For analytical control, chiral confirmation is the critical specification and should not be treated as optional. Require optical rotation or chiral chromatography establishing the D-form, and specify the isomer by CAS number: D- at 1783-96-6, L- at 56-84-8, DL- at 617-45-8. A standard amino acid assay will not distinguish them, and because the D-form carries a substantial price premium driven by the supplement market, the economic incentive runs toward supplying L- against a D- specification. Specify L-aspartic acid content as a limit test, which is the direct measure of enantiomeric purity.
Beyond chirality, standard coverage applies: heavy metals, residual solvents, microbiological limits, loss on drying and sulphated ash, with the production route named. Where the material derives from resolution of the racemate, the resolving agent and its residual limit should be specified; where an enzymatic route is used, the enzyme source should be stated for certification purposes. D-aspartic acid is synthetic or enzymatically produced rather than plant-extracted, so phytosanitary certification does not apply.
One point for customer-facing documentation. The most charitable reading of the evidence is that the original finding may have been real in a population unlike the one later studied — untrained men, possibly with lower baseline androgen status, differ from resistance-trained men near a physiological ceiling, and an effect could exist in the former and not the latter. The trials to test that have not been run. That is a reasonable hypothesis and it is not a claim; presenting it as one would be the same error the category already made. The defensible position is that D-aspartate is interesting endogenous biology, that oral supplementation has been tested in trained men and did not work, and that anyone selling it on the 2009 study should be shown the three trials that followed.
Frequently Asked Questions — D-Aspartic Acid
Does D-aspartic acid raise testosterone?
Not in the population products target. One 2009 study reported increases in luteinising hormone and testosterone at about 2.7 g daily for 12 days. Subsequent trials in resistance-trained men at 3 g for 28 days found no change, and a trial examining 3 and 6 g found no increase at either — with total testosterone lower in the 6 g arm. Meta-analytic appraisal finds no effect.
So should I just dose higher?
The evidence argues directly against that. The trial examining 6 grams reported lower total testosterone than control. Proposed explanations involve D-aspartate oxidase upregulation or pathway feedback, which is plausible but unestablished. Either way, a dose-escalation recommendation runs against the available data.
Is the underlying biology real?
Yes, and it should not be dismissed with the claim. D-aspartate occurs naturally in pituitary, testes and pineal tissue, varies with development and endocrine state, is degraded by a dedicated enzyme (D-aspartate oxidase) and generated by racemase activity. Rodent and in vitro work supports roles in gonadotropin release and Leydig cell steroidogenesis. The translation to oral supplementation is what failed.
Could the original study still have been right?
Possibly, for a different population. The original cohort differed from the later resistance-trained cohorts in training status and probably baseline androgen status, and an effect in untrained or lower-baseline men could be absent in trained men near a physiological ceiling. Those trials have not been run. That is a hypothesis, not a claim.
How do I make sure I receive the D-form?
Chiral confirmation, as a specification requirement rather than an option. Require optical rotation or chiral chromatography, specify the isomer by CAS number — D- 1783-96-6, L- 56-84-8 — and specify L-aspartic acid content as a limit test. A standard amino acid assay will not distinguish them, and the premium sits on the D-form.
Can I use it in a liquid?
Not as the free acid at meaningful concentration — it dissolves at around 0.5 g per 100 ml at room temperature, like the L-form. Solubility rises sharply with pH as the carboxyls deprotonate, so a sodium or potassium salt is the practical route for liquids.